ENTA News and Press, Enanta Pharmaceuticals Inc. From 05/06/21

Updating the results from the first two dose cohorts of Part 2 of its Phase 1b study, Enanta Pharmaceuticals ([[ENTA]] -2.1%) said that its experimental therapy, EDP-514 yielded positive data in a certain segment of chronic hepatitis B virus ((HBV)) patients.The pharmacokinetics obs...

Reported Positive Data from a Phase 1b Study of EDP-514 in NUC-Suppressed Chronic Hepatitis B Virus (HBV) Patients Supporting Once Daily Dosing and Combination Approach On Track to Report Preliminary Data from a Phase 1b Study of EDP-514 in Viremic Chronic HBV Patients in Q2...

Positive Data from First Two Dose Cohorts: 200 mg and 400 mg of EDP-514 EDP-514 was Safe and Well-Tolerated with Pharmacokinetics Supportive of Once Daily Dosing Patients Dosed with EDP-514 for 28 Days Showed a Mean Reduction in HBV RNA of 1 Log Enanta Pharma...

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating and developing small molecule drugs for viral infections and liver diseases, today announced that it plans to report its financial results for its fiscal second quarter ended March 3...

Enanta's huge cash holdings are very desirable in an uncertain economic world and overvalued U.S. stock market setup. The drug trial pipeline could have several positive news developments in the coming months. Improved technical trading momentum since December may be discounting a...

Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will present at the SVB Leerink 10 th...

Image source: The Motley Fool. Enanta Pharmaceuticals Inc (NASDAQ: ENTA) Q1 2021 Earnings Call Feb 8, 2021 , 4:30 p.m. ET Operator Continue reading For further details see: Enanta Pharmaceuticals Inc (ENTA) Q1 2021 Earnings Call Transcrip...

Enanta Pharmaceuticals, Inc. (ENTA) Q1 2021 Earnings Conference Call February 08, 2021 4:30 PM ET Company Participants Jennifer Viera - Investor Relations Jay Luly - President & Chief Executive Officer Paul Mellett - Chief Financial Officer Conference Call Participants Roy Buchanan - JMP ...

Enanta Pharma (ENTA): FQ1 GAAP EPS of -$0.41 beats by $0.39.Revenue of $31.74M (-39.6% Y/Y) beats by $4.01M.Royalty Revenue for the quarter was $31.7M.Cash and marketable securities totaled $404.7M at Dec. 31, 2020.Press Release For further details see: Enanta Pharma EPS beats by $0.39,...

Broadened Hepatitis B Virus (HBV) Program with EDP-721, a New Oral HBV RNA Destabilizer, as a Potential Component of a Functional HBV Cure Regimen; Plan to Initiate Phase 1 Study Mid-2021 Initiated RSVTx, a Phase 2b Study of EDP-938 in Adult Hematopoietic Cell Transplant Rec...